PAVmed (NASDAQ:PAVM) Rating Lowered to Hold at ValuEngine

ValuEngine lowered shares of PAVmed (NASDAQ:PAVM) from a buy rating to a hold rating in a research report report published on Friday morning, ValuEngine reports.

Separately, Maxim Group set a $8.00 target price on TrovaGene and gave the stock a buy rating in a report on Thursday, May 23rd.

PAVmed stock opened at $1.05 on Friday. The business has a fifty day moving average of $1.11. PAVmed has a 12 month low of $0.86 and a 12 month high of $1.70.

PAVmed (NASDAQ:PAVM) last released its earnings results on Tuesday, May 21st. The company reported ($0.09) EPS for the quarter.

In other PAVmed news, CEO Lishan Aklog purchased 30,000 shares of the firm’s stock in a transaction dated Thursday, May 23rd. The stock was purchased at an average price of $1.10 per share, for a total transaction of $33,000.00. Following the completion of the purchase, the chief executive officer now directly owns 848,413 shares of the company’s stock, valued at $933,254.30. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 34.40% of the stock is owned by insiders.

PAVmed Company Profile

PAVmed Inc operates as a medical device company in the United States. The company's lead product pipeline includes CarpX, a percutaneous device to treat carpal tunnel syndrome; EsoCheck, an non-invasive cell collection device and DNA biomarkers to detect esophageal cancer precursor; PortIO, an implantable intraosseous vascular access device; and DisappEAR, an antimicrobial resorbable ear tube.

See Also: No Load Funds

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for PAVmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAVmed and related companies with MarketBeat.com's FREE daily email newsletter.